J Korean Cancer Assoc.  1999 Dec;31(6):1246-1252.

Local Immunotherapy to Treat Metastatic Liver Cancer by Biodegradable Microspheres Containing Interleukin - 2

Affiliations
  • 1Department of Surgery, Ajou University School of Medicine, Suwon, Korea.
  • 2Department of Biomedical Engineering, Johns Hopkins University Baltimore, Maryland.

Abstract

PURPOSE: We tried to elucidate antitumor effect of interleukin-2 containing miscrospheres (IL-2 MS) against intrahepatic challenge of parental cancer cells, which is clinically relevant tumor model.
MATERIALS AND METHODS
Using a model of liver metastasis by intrahepatic challenge of CT-26 murine colon carcinoma cells to syngeneic BALB/c mice, IL-2 MS were given with parental tumor cells, or intratumorally in animals with established tumors. Tumor volume and survivals were determined.
RESULTS
Animals receiving IL-2 MS showed significant tumor suppression effect and systemic protection against the hepatic challenge of parental tumor cells after concomitant challenge with parental CT-26. In animals with established hepatic tumors, significant prolongation in survival was noted.
CONCLUSION
IL-2 MS was effective for the protection of host agaisnt the metastatic hepatic tumor when administered with tumor cells. Its efficacy against the established tumor was also significant as in protection. Locally administered IL-2 MS can obviate the high- efficiency gene transfer technique and ex vivo culture of autologous tumor cells in gene transduced autologous tumor vaccine. It can also provide support for the specific immuno- therapy for the metastatic liver cancer.

Keyword

Interleukin-2; Microsphere; Intratumoral administration

MeSH Terms

Animals
Colon
Gene Transfer Techniques
Humans
Immunotherapy*
Interleukin-2
Interleukins*
Liver Neoplasms*
Liver*
Mice
Microspheres*
Neoplasm Metastasis
Parents
Tumor Burden
Interleukin-2
Interleukins
Full Text Links
  • JKCA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr